DPR & CMA Data on I.v. fluid (bfs technology) | i.v. fluid (ffs technology) | i.v.fluid (ffs technology)

The project focuses on the development and production of intravenous (i.v.) fluids utilizing BFS (Blow-Fill-Seal) and FFS (Form-Fill-Seal) technologies. These technologies offer advanced methods for the manufacturing of sterile solutions, ensuring safety, stability, and efficiency. BFS technology is known for its capability to produce flexible, single-use, aseptic containers that minimize the risk of contamination while enhancing shelf life. On the other hand, FFS technology combines filling and sealing in a continuous process, allowing for high-speed production of various container sizes. This project aims to cater to the increasing demand for intravenous fluids in hospitals and healthcare facilities, particularly in emergency care, surgeries, and critical care units. As the healthcare industry evolves, the necessity for dependable and sterile drug delivery systems remains paramount. The introduction of these two technologies ensures not only quality but also cost-effectiveness in the manufacturing process, making it an attractive investment for pharmaceutical companies. Moreover, advancements in technology and materials science will further enhance the product offerings, meeting regulatory standards while ensuring patient safety. The global market for I.V. fluids is expected to grow due to factors such as rising diseases requiring intravenous therapy, increased surgical procedures, and the growing geriatric population. With the dual implementation of BFS and FFS technologies, the project is set to define a new standard in i.v. fluid production that aligns with the modern healthcare ecosystem.

• Rising demand for IV fluids due to increase in chronic illnesses.
• Growing surgical procedures leading to a higher need for IV therapy.
• Expansion in the geriatric population contributing to the market growth.
• Increased focus on sterile and safe drug delivery systems.
• Advancements in manufacturing technologies improving production efficiency.

Total capital investment ranges from ₹495,000 to ₹68,200,000 depending on the scale of operation. This covers plant and machinery, civil work, pre-operative expenses, and working capital. Larger scales require proportionally higher investment but typically offer better returns.

At the larger investment scale, the expected break-even is approximately approx. 4 years at approximately 40.00% capacity utilisation. Smaller setups may reach break-even sooner due to lower fixed costs relative to the capacity.

• Polyvinyl Chloride (PVC)
• Polyethylene (PE)
• Sterile water for injection
• Active pharmaceutical ingredients (APIs)
• Additives for stability and preservation

• High sterility assurance through advanced manufacturing methods.
• Cost-effective production enabled by BFS and FFS technologies.
• Scalability of manufacturing processes to meet varying demand.
• Reduced risk of contamination leading to improved patient safety.